All In Biotech

Drug Trial Radar · NCT06902090

Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Jul 5, 2023

Primary completion

Jul 25, 2023

Study completion Aug 25, 2023

Sponsor

Sponsor type
Industry
First posted
Mar 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objective:To compare the pharmacokinetic profiles between meloxicam nanocrystal injection (strength: 1 mL: 30 mg, Yangtze River Pharmaceutical Group Co., Ltd.) and the originator meloxicam nanocrystal injection (trade name: ANJESO®, strength: 1 mL: 30 mg, Baudax Bio Inc.) in healthy volunteers. Secondary Objective:To observe the safety and tolerability of meloxicam nanocrystal injection and ANJESO® in healthy volunteers.

Conditions

  • Pain

Interventions

  • Meloxicam Nanocrystal Injection(Yangtze River Pharmaceutical Group Co., Ltd.)Drug

    IV, 30 mg

  • Meloxicam Nanocrystal Injection (ANJESO®)Drug

    IV, 30 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax (Maximum drug plasma concentration)Time frame: up to 96 hours after drug administration
  2. Tmax (Time to achieve Cmax)Time frame: up to 96 hours after drug administration
  3. AUC0-t (Total area under the plasma drug concentration-time curve from time of administration to the time of the last quantifiable drug concentration)Time frame: up to 96 hours after drug administration
  4. AUC0-∞ (Total area under the plasma drug concentration-time curve)Time frame: up to 96 hours after drug administration
  5. T1/2z (Apparent terminal elimination half-life)Time frame: up to 96 hours after drug administration
  6. λz (Apparent terminal elimination rate constant)Time frame: up to 96 hours after drug administration
  7. AUC_%Extrap (The percentage of the portion estimated through extrapolation)Time frame: up to 96 hours after drug administration
  8. Vz (Volume of distribution during the terminal phase)Time frame: up to 96 hours after drug administration
  9. CLz (Clearance of the analyte in plasma)Time frame: up to 96 hours after drug administration
  10. Occurence of adverse eventsTime frame: up to 15 days of each treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.